Ellume

About

Ellume builds connected diagnostic tests using fluorescent immunoassay and quantum-dot detection for at-home Bluetooth-linked antigen testing, point-of-care ellume·lab, and high-throughput laboratory assays, with manufacturing expansion.

Mission

Ellume develops and commercializes connected diagnostic products built on a fluorescent immunoassay platform and a quantum dot nanoparticle detection system. The company created three COVID-19 antigen tests tailored for at-home, point-of-care (ellume·lab) and high-throughput laboratory settings, each delivering results in under 15 minutes. Its at-home product uses a Bluetooth-connected analyzer and a smartphone app to reduce human error, issue digital certificates, and enable real-time cloud reporting for contact tracing. Ellume has partnerships with GlaxoSmithKline for consumer health and with QIAGEN to bring a high-throughput version of ellume·lab to the U.S. The company is expanding manufacturing with a new facility in Brisbane, Australia that will begin production imminently, and U.S. launches are planned upon receipt of FDA Emergency Use Authorization. The NIH RADx Phase 2 award announced here is intended to accelerate clinical testing and manufacturing scale-up of these tests.

Quick Facts